Abstract
Introduction Breast cancer is the most common cancer in women in Saudi Arabia and the world (WHO 2020). Several studies have been published, worldwide, about the prognostic indicators of breast cancer, many of them showed a characteristic distribution according to certain geographical areas
Methods Over 20 years (1998-2018), the results of 498 patients diagnosed with breast cancer, have been collected from the archive of the pathology department at King Fahd University Hospital (KFHU).
Results This study included 498 patients diagnosed with breast cancer at King Fahd University Hospital over 20 years period (1998-2018), 58.4% (n=291) were Saudis. Data analysis showed a wide age distribution of breast cancers among eastern Saudi patients; however, most cases were seen in the 3rd and 4th decades. Luminal B was the most common subtype followed by triple-negative and luminal-A. Statistical analysis revealed a significant negative relationship between Saudi patients’ age at diagnosis and Her2 expression (P= .030), interestingly, this association was not significant in none-Saudi patients (P= .528).
Discussion/Conclusion Our data revealed that breast cancer in Eastern Province had similar prognostics to international findings, however, Her2 profile and molecular subtype among Eastern Saudi women showed a minor deviation from worldwide published data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is self-funded by th author.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval is granted by the SCRELC (Standing Committee on Research Ethics on Living Creatures), Institutional review board at Imam Abdulrahman Bin Faisal University, IRB-2020-1-262. Informed patient consent was waived due to the use of archival data of anonymous nature that does not disclose patients' identity.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are not available for public use.
